NIH study confirms that Avastin and Lucentis, when administered monthly or as-needed for two years, are equivalent in treating age-related macular degeneration. These are the new findings from the National Institutes of Health (NIH) sponsored Comparison of AMD Treatments Trials (CATT). Second-year results for the Comparison of AMD Treatments Trials (CATT) Study were just published Monday, April 30th, in the journal Ophthalmology. Avastin and Lucentis are the two most widely used drugs to treat wet age-related macular degeneration (AMD), which is the leading cause of vision loss and blindness in older Americans. The CATT Study, which was designed to compare administration of Avastin and Lucentis by assigning patients to one of four treatment groups, found that the two drugs are both highly effective at improving vision when administered either monthly or on an as-needed basis; however, greater improvements in vision were seen with monthly administration. The first-year findings (that both drugs are equally effective at treating AMD) were published in the New England Journal of Medicine on May 19, 2011, and were significant because Avastin is a much less expensive drug than Lucentis.Lawrence J. Singerman, MD of Retina Associates was a Principal Investigator for the CATT Study, and Retina Associates of Cleveland was one of only 2 centers in Ohio with patients enrolled in the Study. Retina Associates was recognized one year ago as a "Center of Excellence" for their follow-up success with CATT Study patients - only 9 centers out of 44 worldwide achieved this recognition. The other center in Ohio to enroll patients in CATT was the Ohio State University Medical Center.
To view of copy of the April 30, 2012 NIH/NEI press release (two year results) click here.
To view the publication in Ophthalmology magazine (2012), click here.
To view a copy of the April 28, 2011 NIH/NEI press release (one year results) click here